First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update
Authors
Falchi, L.Offner, F.
Belada, D.
Brody, J.
Linton, Kim M
Karimi, Y.
Cordoba, R.
Snauwaert, S.
Abbas, A.
Wang, L. W.
Wu, J.
Elliott, B.
Clausen, M. R.
Affiliation
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY;Issue Date
2022
Metadata
Show full item recordCitation
Falchi L, Offner F, Belada D, Brody J, Linton KM, Karimi Y, et al. First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301984.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.7523Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7523Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.7523